echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily O drug four-link program first-line treatment of late non-scale NSCLC results are positive.

    Research and development daily O drug four-link program first-line treatment of late non-scale NSCLC results are positive.

    • Last Update: 2020-10-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.09.23 Research and Development NEWS: Key clinical trial results of Blueprint precision KIT inhibitors were positive; Kangzhe Pharmaceuticals/Sun Pharmaceuticals Terraju single-dose clinical treatment of moderate to severe psoriasis; Sansheng Jian anti-IL-4R alpha monoantigene clinical trial approved by NMPA; Da'an gene new coronavirus detection products were certified as medical devices...... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original article) Blueprint Precision KIT Inhibitor Key Clinical Trial Results Positive Blueprint Pharmaceuticals announced today that its precision therapy Avakit (avapritinib) has obtained positive top-line results in Phase 1 clinical trials for patients with advanced systemic hypertrophic hypertrophic disorder, EXPLORER and Phase 2 clinical trial PATHFINDER.
    data show that precision KIT inhibitor Ayvakit significantly reduces the load on hypertrophoblast cells, patients exhibit high total and total remission rates, and long-lasting clinical benefits.
    O drug, chemotherapy, beval single-cell treatment of advanced non-scale NSCLC research, 2020 ESMO showed a phase IB study (ONO-4538-04) results, the results show that Navuliyu monoantigen (O drug) combined carbab, yew alcohol and beva bead monoantigen treatment of late NSCLC, with resistance to safety and promising efficacy.
    21st, Kangfang BioPD-1/VEGF dual anti-AK112 initiated clinical 21st, Kangfang Bio started AK112 treatment of advanced solid tumor phase I/II clinical.
    AK112 is Kangfang's second clinical dual-anti-product, targeting PD-1/VEGF.
    Conzhe Pharmaceuticals / Sun Pharmaceuticals Tyraju monoantitor Phase III clinical treatment of moderate to severe psoriasis 21, Kangzhe Pharmaceuticals / Sun Pharmaceuticals Tildrakizumab (Tirajuda monoder) treatment of moderate to severe plaque psoriasis Phase III clinical first publicity.
    Drug Approval: BMS/Bluebird Bio multiple myeloma CAR-T therapy received FDA Priority Review 22, BMS and Bluebird Bio announced that the FDA has accepted and granted its biological products license application priority review, for research B cell mature antigen (BCMA) guidance The chimic antigen recipient (CAR) T-cell immunotherapy idecabtagene vicellel (also known as bb2121) is used to treat adult multiple myeloma patients who have received at least three treatments, including immunomodulants, protease inhibitors, and anti-CD38 antibodies.
    Sansheng Guojian anti-IL-4R alpha monoantigen clinical trial was approved by NMPA on the 22nd, Sansheng Pharmaceuticals announced that its Sansheng Guojian Pharmaceuticals (Shanghai) Co., Ltd. independently developed anti-white melebin 4-subject alpha (IL-4R alpha) human-origin monoclonal antibody drug recently obtained NMPA approval to carry out clinical trials of adult moderate severe specific dermatitis patients requiring systematic treatment.
    addition, the product in the United States clinical Phase I trial recently completed the first subjects into the group.
    Bayda Pharmaceuticals "Ektini" new adaptive report listed on the 22nd, Beda Pharmaceuticals issued a notice that the company declared the hydrochloric acid ecstasy (commodity name: Kemera ®) a third application for the listing of adaptive diseases was accepted by NMPA, adaptive diseases for postoperative auxiliary treatment.
    second-generation SINE compound! Deqi Pharma Class 1 new drugs in China declared clinical acceptance 22, CDE publicity, Deqi Pharmaceuticals Class 1 new drug ATG-016 tablets (eltanexor) clinical trial applications were accepted.
    this is a second-generation SINE compound that initially showed a larger therapeutic window, and this is the first time that ATG-016 has been declared clinical in China, according to CDE's official website.
    Koren medium long chain fat milk / amino acids (16) / glucose (30%) injection first imitation listed on the 22nd, Colum Pharmaceuticals 3 classes of generic drugs "medium long chain fat milk / amino acids (16)/ glucose (30%) injection" listing application was accepted by CDE, the first domestic market.
    Zhifei biorovirus inactivated vaccine to obtain clinical trial approval notice 23, Zhifei Biological announced that the company on September 22, 2020 received a wholly-owned subsidiary Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. report, developed by Zhifei green bamboo roil virus inactivated vaccine to obtain the National Drug Administration drug clinical trial approval notice, agreed to this product for clinical trials, its clinical trial application was accepted on June 24, 2020.
    Da'an gene new coronavirus detection products by the medical device registration certificate 23, Daan gene issued a notice that recently, the company's new coronavirus 2019-nCoV nucleic acid testing kit (fluorescent PCR method) to obtain the National Drug Administration issued a medical device registration certificate.
    Jiangsu Wu Zhong injection with Esomeprazole sodium obtained the drug registration certificate 23, Jiangsu Wu Zhong issued a notice that recently, Jiangsu Wu Chinese Medicine Group Co., Ltd., a subsidiary of Jiangsu Wu Chinese Medicine Group Co., Ltd. Suzhou Pharmaceutical Factory received the State Drug Administration approved the issuance of injection of Esomerazole sodium "drug registration certificate."
    the first Ida Lafeng injection for ALS listing recently, NMPA approved Nanjing Synthesic Dongyuan Pharmaceutical Co., Ltd. must save ® (Ida Lafeng injection, including 5 ml: 10mg, 20ml: 30mg two specifications) new adaptive disorders for the treatment of freezing human disease (ALS).
    is the world's second and first domestic-listed Idalaven injection.
    28 drug approval documents such as Grillo tablets, injection omaju monoantitor, etc. to be received on the 23rd, NMPA issued drug approval documents to be received information, including the first three total Lozolofen sodium tablets, stone drug Otigrilo tablets, Beijing Novartic Pharmaceutical injection omaju monoantigen tablets and other 28 drugs.
    Zhengda Qing Kagli net tablets are about to be reviewed recently, NMPA data show that Zhengtian Qing Pharmaceutical Group's Kagle net tablets 4 imitation listing applications entered the "in the approval" state, if successfully approved will become the second after Howson.
    Haisco Pei pulistamin tablets reviewed in recent days, NMPA official website data show that Hesco's Pescopristamin tablets 4 imitation listing applications into the "in the approval" stage.
    : Siemens and Novaral have announced a partnership to design, develop and commercialize diagnostic tests for Novaral's therapeutic product line.
    collaboration between the two companies is the immunometric determination of serum nerve wire light chain (NfL) in patients with multiple sclerosis (MS) and other neurological disorders.
    Pharmaceuticals and Minoryx reached an agreement on the innovative rare disease drug Leriglitazone 23, Shufang Pharmaceuticals and Minoryx Therapeutics announced an exclusive licensing agreement for the innovative rare disease drug Leriglitazone.
    Leriglitazone is a disease-modified PPAR gamma astrist for Minoryx that penetrates the blood-brain barrier.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.